Management of Heart Failure, Durable Left Ventricular Assist Device, and Heart Transplant Patients in the COVID-19 Era

Nadia Fida

doi:10.14797/mdcvj.651

Management of Heart Failure, Durable Left Ventricular Assist Device, and Heart Transplant Patients in the COVID-19 Era

Nadia Fida

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Abstract

Our world is facing recurrent waves of coronavirus disease 2019 (COVID-19) with the emergence of more infectious strains of the novel coronavirus, SARS-CoV-2. Multiple studies have established that heart failure (HF) patients are at high risk of severe disease and poor outcomes with COVID-19. Management of COVID-19 in patients with HF, heart transplant, and those supported with durable left ventricular assist devices present an arduous challenge due to underlying complex health conditions and overlap of symptoms. Based on available data, this review outlines the management of this vulnerable patient population who either present with COVID-19 with preexisting HF or with de novo HF from COVID-19.

Original language	English (US)
Pages (from-to)	63-72
Number of pages	10
Journal	Methodist DeBakey cardiovascular journal
Volume	17
Issue number	5
DOIs	https://doi.org/10.14797/mdcvj.651
State	Published - 2021

Keywords

COVID-19
heart failure
heart transplant
left ventricular assist device

ASJC Scopus subject areas

General Medicine

Access to Document

10.14797/mdcvj.651

Cite this

@article{4167d22448d64de4bf0a1579ecdc78fb,

title = "Management of Heart Failure, Durable Left Ventricular Assist Device, and Heart Transplant Patients in the COVID-19 Era",

abstract = "Our world is facing recurrent waves of coronavirus disease 2019 (COVID-19) with the emergence of more infectious strains of the novel coronavirus, SARS-CoV-2. Multiple studies have established that heart failure (HF) patients are at high risk of severe disease and poor outcomes with COVID-19. Management of COVID-19 in patients with HF, heart transplant, and those supported with durable left ventricular assist devices present an arduous challenge due to underlying complex health conditions and overlap of symptoms. Based on available data, this review outlines the management of this vulnerable patient population who either present with COVID-19 with preexisting HF or with de novo HF from COVID-19.",

keywords = "COVID-19, heart failure, heart transplant, left ventricular assist device",

author = "Nadia Fida",

note = "Publisher Copyright: {\textcopyright} 2021 The Author(s).",

year = "2021",

doi = "10.14797/mdcvj.651",

language = "English (US)",

volume = "17",

pages = "63--72",

journal = "Methodist DeBakey cardiovascular journal",

issn = "1947-6094",

publisher = "Methodist DeBakey Heart & Vascular Center",

number = "5",

}

TY - JOUR

T1 - Management of Heart Failure, Durable Left Ventricular Assist Device, and Heart Transplant Patients in the COVID-19 Era

AU - Fida, Nadia

PY - 2021

Y1 - 2021

N2 - Our world is facing recurrent waves of coronavirus disease 2019 (COVID-19) with the emergence of more infectious strains of the novel coronavirus, SARS-CoV-2. Multiple studies have established that heart failure (HF) patients are at high risk of severe disease and poor outcomes with COVID-19. Management of COVID-19 in patients with HF, heart transplant, and those supported with durable left ventricular assist devices present an arduous challenge due to underlying complex health conditions and overlap of symptoms. Based on available data, this review outlines the management of this vulnerable patient population who either present with COVID-19 with preexisting HF or with de novo HF from COVID-19.

AB - Our world is facing recurrent waves of coronavirus disease 2019 (COVID-19) with the emergence of more infectious strains of the novel coronavirus, SARS-CoV-2. Multiple studies have established that heart failure (HF) patients are at high risk of severe disease and poor outcomes with COVID-19. Management of COVID-19 in patients with HF, heart transplant, and those supported with durable left ventricular assist devices present an arduous challenge due to underlying complex health conditions and overlap of symptoms. Based on available data, this review outlines the management of this vulnerable patient population who either present with COVID-19 with preexisting HF or with de novo HF from COVID-19.

KW - COVID-19

KW - heart failure

KW - heart transplant

KW - left ventricular assist device

UR - http://www.scopus.com/inward/record.url?scp=85123269737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85123269737&partnerID=8YFLogxK

U2 - 10.14797/mdcvj.651

DO - 10.14797/mdcvj.651

M3 - Review article

C2 - 34992724

AN - SCOPUS:85123269737

SN - 1947-6094

VL - 17

SP - 63

EP - 72

JO - Methodist DeBakey cardiovascular journal

JF - Methodist DeBakey cardiovascular journal

IS - 5

ER -

Management of Heart Failure, Durable Left Ventricular Assist Device, and Heart Transplant Patients in the COVID-19 Era

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this